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implicated as a regulator of estrogen-mediated cell proliferation.
Apoptosis and cell protection: TOX3 was demonstrated to be
expressed downstream of a cytoprotective cascade together with
CITED1, a transcriptional regulator that does not bind directly to
DNA and enhances transcription mediated by diverse transcription
factors, such as estrogen receptors, SMAD, or early growth response
(EGR) 2. CITED1 expression parallels with estrogen receptors ERa
and ERb.
TOX3 over-expression protects neuronal cells from cell death
caused by endoplasmic reticulum stress or BAX over-expression
through the induction of repression of pro-apoptotic transcripts and
anti-apoptotic transcripts, which associates with enhanced transcrip-
tion implicating isolated estrogen-responsive elements (ERE) and
estrogen-responsive promoters. TOX3 also interacts with native
CREB and induces the CREB-responsive BCL-2 promoter. Co-
expression of CITED1 inhibits the CREB-responsive BCL-2 pro-
moter and by contrast, co-expression of CREB inhibits TOX3-medi-
ated transcription from the estrogen-responsive complement C3
promoter. Results have suggested that TOX3 can mediate cytoprotec-
tive transcription from the BCL-2 promoter or the complement C3
promoter, based on the predominance of either phosphorylated
CREB or CITED1 within the transcriptionally active complex.
Regulation of estrogen: TOX3 is also shown to regulate Trefoil
Factor Family 1 (TFF1), the estrogen-regulated protein, in an estro-
gen-independent and tamoxifen-insensitive way. TFF1, a small cys-
teine-rich secreted protein, is normally expressed at highest levels
in the mucosa of the gastrointestinal tract and also is extensively
expressed at high levels in malignant breast epithelial cells where
its expression is regulated by estrogen. Even in the absence of estro-
gen, TFF1 was upregulated by TOX3. Additionally, TOX3 induces
enhancer RNAs that have been involved in TFF1 gene regulation.
FOXA1 and ESR1: It is known that a SNP near its 5ʹend and pro-
moter appears to be strongly associated with breast cancer suscepti-
bility. Breast cancereassociated SNPs are also enriched for FOXA1
and ESR1 transcription factorebinding sites and H3K4me1 histone
modification. This SNP alters a FOXA1, a protein required for estro-
gen receptor-a (ER) function, with disease susceptibility associated
with enhanced FOXA1 binding, disordered enhancer function, and
a reduce in TOX3 gene expression. The data may offer a validation
for prophylactic treatment of high-risk patients with FOXA1
inhibitors.
TOX3 and bone metastasis of breast cancer: Some TOX3
expressing tumors are linked with adverse outcome, and increased
expression of TOX3 mRNA that has been involved in breast cancer
metastatic to bone. In microarray analysis, between the genes upregu-
lated by TOX3 was the well-investigated pro-metastatic gene CXCR4.
It has been indicated that IGF-1 cooperates with CXCR4 signaling to
advance bone marrow metastasis of breast cancer, potentially one fac-
tor in the aggressive behavior of LumB tumors. Since CXCR4 is
upregulated by TOX3 and is highly expressed in LumB tumors,
this could improve the migratory properties of MCF-7 cells. There-
fore, IGF-1 could play a role in regulation of TOX3 expression.
MCF-7 cells treated with IGF-1 indicated significant, albeit modest,
upregulation of TOX3 expression, as well as the known IGF-1 target
gene GAPDH.
TOX3+ and therapeutic modalities for breast cancer: TOX3
expression is regarded a tumor promoter rather than a tumor sup-
pressor in breast cancer. It has been suggested that TOX3 expres-
sion decreases in breast cancer and is correlated with the disease
risk. Furthermore, TOX3 has the potential to regulate ER targetgene expression in the appearance of limiting concentrations of
estrogen. This potential property underlines the treatment modal-
ities for TOX3+ breast cancer. It is also suggested that TOX3 and
related biomarkers, such as SCUBE2, TFF1, TFF3, AGR2, CEA-
CAM6, TSPAN1 or CXCR4 are helpful for the diagnosis, prognosis
and treatment as well as classification of different breast cancer
subtypes. Knocking down of TOX3 by siRNA suggests that even
low levels of TOX3 may affect estrogen activation of the TFF1
gene.
Additionally, estrogen treatment in cells over-expressing TOX3
results in a hyper-responsive TFF1 gene expression. Expression of
TOX3 may be implicated in the resistance to endocrine therapy which
may occur in some LumB cancers. In this respect, cells over-express-
ing TOX3 had a better capability to survive under estrogen-deprived
conditions.
IGF-1 treatment in MCF-7 cells can also cause TOX3 up-regula-
tion. This growth factor has been shown to result in breast cancer
development and endocrine resistance during stabilization of
FOXA1 protein in MCF-7 cells. Furthermore, FOXA1 alters the pat-
tern of ER binding in poor outcome/metastatic ER+ breast cancer
leading to a situation similar to that in ER+ good outcome breast
cancer.
Conclusion: TOX3 gene amplification is associated with reduced
risk of the disease and metastasis. TOX3 significantly is associated
with increased breast cancer cell proliferation, migration, survival,
tumor development. Many studies confirm a key role for TOX3 in
breast cancer pathology. However, TOX3 plays dual and conflicting
roles in cancer initiation and progression which remains to be inves-
tigated.
Use of bacterial ghosts as novel drug delivery systems to
improve cancer treatment
Amin Afkhami-Poustchi a, Maryam M. Matin a,b,c,*
a Department of Biology, Faculty of Science, Ferdowsi University of
Mashhad, Mashhad, Iran b Cell and Molecular Biotechnology
Research Group, Institute of Biotechnology, Ferdowsi University of
Mashhad, Mashhad, Iran c Stem Cell and Regenerative Medicine
Research Group, Iranian Academic Center for Education, Culture
and Research (ACECR), Khorasan Razavi Branch, Mashhad, Iran
E-mail address: matin@um.ac.irExtended Abstract
Introduction: The bacterial ghost (BG) system represents a novel
and progressive approach in the development of bacterial mediated
cancer immunotherapy. The empty inner space of BGs can be filled
with drugs, proteins, DNA, enzymes and other compounds. The
induced lysis process does not harm the essential structural compo-
nents of the bacteria, giving rise to immunologically active particles
capable of stimulating the host immune system and delivering spe-
cific antigen (Ag) to professional antigen-presenting cells (APCs)
or active substances to the target cells.
Production of bacterial ghosts: BGs are produced by expression
of cloned gene E from bacteriophage fX174 resulting to cell lysis in
Gram-negative bacteria, such as, Escherichia coli K12 strains, Kleb-
siella pneumoniae, Mannheimia (Pasteurella) haemolytica, Neisseria
meningitidis, Salmonella typhimurium, Vibrio cholera, Helicobacter
pylori, and others. Expression of gene E can be placed under tran-
scriptional control of either the thermo sensitive EpL/pR-cI857 pro-
moter, or under chemical inducible promoter repressor systems, like
lacPO or the tol expression system.
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fusion of the inner and outer cell membranes, forming a specific
transmembrane tunnel structure through which all the cytoplasmic
content is expelled, thus leaving a bacterial envelope called a BG
devoid of nucleic acids, ribosomes and other intracellular constitu-
ents. The inner membrane (IM) and outer membrane (OM) structures
of BGs remain intact during the lysis process. Electron microscopy
studies and enzymatic studies clearly showed a sealed periplasmic
space at the border of the lysis tunnel. The efficiency of the E-medi-
ated lysis process, and quantification of generated BGs and non lysed
viable bacteria are determined by flow cytometry assays using a spe-
cific dye that is sensitive to the changes of discriminatory power of
membrane potential and stains only cells that have lost membrane
potential (BGs or dead bacteria).
Bacterial ghosts as advanced drug delivery systems: Many dis-
eases including cancers require the systemic administration of highly
aggressive drugs to already immunocompromised patients. Deleteri-
ous and often severe side effects result from a lack of cellular and tis-
sue selectivity. Another major issue is the poor solubility of some
drugs used in cancer treatment. Considering these limitations, the
development of a safer and more efficient drug delivery system
(DDS) is the priority for future advanced cancer treatments. Recently,
bacterial ghosts made from the colonic commensal Mannheimia hae-
molytica were used for in vitro delivery of doxorubicin (DOX) to
human colorectal adenocarcinoma (Caco-2) cells.
Adherence studies showed that the M. haemolytica ghosts targeted
the Caco-2 cells and released the loaded DOX within the cells. Cyto-
toxicity assays showed a two folds enhancement in cytotoxic and
anti-proliferative activity in cells incubated with DOX-loaded ghosts
as compared with cells for which DOX was directly added to the cul-
ture media. This phenomenon might be caused by degradation of
DOX-loaded BGs within the endo-lysosome of target cells allowing
DOX to bypass the multi-drug resistance (MDR) efflux pumps and
resulting in enhanced accumulation of DOX in the cytoplasm and
then in the nuclear area of target cells. Current work with bacterial
ghosts lies in the investigation of the carrier capacity of the cytoplas-
mic lumen. This intracellular space of BGs can be filled either with
water-soluble substances or emulsions such that the drug(s) of interest
can be coupled to streptavidin anchored on the inside of the cytoplas-
mic membrane. Moreover, bacterial ghosts can be filled and sealed
for the delivery of fluid, non-anchored substances. In a recent study,
E. coli ghosts were filled with the reporter substance calcein and were
sealed by fusion with membrane vesicles to maintain inner membrane
integrity. Adherence and uptake studies showed that murine macro-
phages and human Caco-2 cells took up the bacterial ghosts, and cal-
cein was released within the cells.
Bacterial ghosts as immunologically active particles: Because
of the unique structure of the BG’s envelope with preserved patho-
gen-associated molecular patterns (PAMPs), BGs can be used in bio-
medicine alone as an adjuvant or as a delivery vehicle for drugs or
genes. The inner space of BG’s empty envelope can be loaded with
a combination of peptides, drugs or foreign DNA which gives us an
opportunity to design new types of polyvalent vaccines. BGs have
excellent DNA loading capacity varying from 4000 to 6000 plasmid
copies per BG depending on the concentrations of DNA solution
used. BGs loaded with plasmid DNA are efficiently internalized
and phagocytozed by both professional APCs and tumor cells.
Cross-presentation of Ag delivered to dendritic cells (DCs) by BGs
can activate both CD4+ and CD8+ T cells and stimulate the immune
system to enhance the immune response against Ag expressed by tar-
get cells. Inner and outer membrane structures of BGs includinglipopolysaccharide (LPS) and other PAMPs remain intact after pro-
tein E-mediated lysis of Gram-negative bacteria. Thus, beside pos-
sessing a high loading capacity; BGs carry highly effective
molecules for the stimulation of cross presentation by DCs on their
surface, specially, tumor-associated antigens (TAAs). BGs with their
intact envelope structures are not only immune stimulatory to profes-
sional phagocytes but are also capable of providing stimulatory sig-
nals to tumor cells. It is known that melanoma cells have the
capacity to behave as non-professional APCs and can phagocyte
both apoptotic and live cells, and it was recently shown that mela-
noma cells actively respond to exposure to BGs by increasing their
rate of phagocytosis. Using BGs for gene delivery to the immuno-
competent cells, in particular DCs as well as tumor cells, could ini-
tiate or restore the immune response against the delivered TAAs as
well as induce and increase the expression of target genes by APCs
and tumor cells.
Conclusions: These observations indicate high capacity of BGs to
target various histological types of cancers. BGs are very useful non-
living carriers, as they can carry foreign antigens, nucleic acids and
drugs in one or more cellular locations simultaneously. Optimization
and improvement of the selected prospective model type of BGs
would help to progress the development of microbial-mediated dis-
ease treatment and drug delivery systems and their application in
future clinical trials.
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Introduction: Cancer is one of the most major and prevalent
health problems around the world that shows high mortality rate.
There have been many researches on the advantages of camel milk
(CM) in cancers. Camel milk is very rich in nutrition and it is used
in the treatment of different diseases. Traditionally, the use of camel
milk in the treatment and prevention of various diseases existed in
Iran, India and Arabic countries. Recent research findings prove the
effectiveness of camel milk in the treatment of diabetes, milk and
food allergies, autism, liver toxicity, hepatitis and cancers. Cell cul-
ture and animal studies introduce camel milk as a new option in can-
cer treatment.
Materials and method: Electronic databases including PubMed,
Scopus, and Cochrane library were searched to access articles giv-
ing any in vitro, in vivo, and human evidences on the efficacy of
CM in the treatment of cancer. Out of 80 records were found in
